High-Dose Erythropoietin in Extremely Premature Infants to Prevent/Attenuate Brain Injury: A Phase II Study

NCT00589953 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Infant, Premature
Erythropoietin
Brain Injury
Intraventricular Hemorrhage
Periventricular Leukomalacia
Neurodevelopmental Outcomes
Randomized Clinical Trial

Interventions

DRUG: Erythropoietin
DRUG: Saline placebo

Sponsor

Atlantic Health System